Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sally Moore

Showing results (51-60 of 69) with videos related to

Pageof 7
Sort By:
Leukemia|September 7, 2024
Plasma cell disorders supress mucosal anti-bacterial immunity: another dimension of immunoparesis in plasma cell neoplasmsSian Faustini, Y L Tracey Chan, Lilli Evans, et al.
British Journal of Haematology|September 4, 2025
Assessment and treatment of frail patientns living with multiple myeloma. A guideline on behalf of the UK Myeloma Research Alliance Frailty GroupSally Moore, Hannah Miller, Christopher Parrish, et al.
British Journal of Haematology|July 10, 2018
A new prognostic model for myeloma patients relapsing from upfront autologous transplantation based on ISS and PFS1Selina J Chavda, Paul M Maciocia, Pavlina Mesiri, et al.
British Journal of Haematology|May 18, 2026
Belantamab mafodotin-associated keratopathy: Clinical outcomes and management from two UK tertiary centresSarah Schimansky, Rebecca Cairns, Nicholas Cotton, et al.
British Journal of Haematology|February 12, 2026
High-throughput monoclonal gammopathy community monitoring programmeGaurav Agarwal, Lauren Campbell, Oluremi Carty, et al.
Brain, Behavior, & Immunity - Health|October 16, 2024
Characterising how a single bout of exercise in people with myeloma affects clonal plasma cell and immune effector cell frequency in blood, and daratumumab efficacy <i>in vitro</i>Harrison D Collier-Bain, Annabelle Emery, Frankie F Brown, et al.
British Journal of Haematology|August 3, 2021
COVID symptoms, testing, shielding impact on patient-reported outcomes and early vaccine responses in individuals with multiple myelomaKarthik Ramasamy, Ross Sadler, Sally Jeans, et al.
Scientific Reports|November 15, 2024
Downhill running does not alter blood C1q availability or complement-dependent cytotoxicity of therapeutic monoclonal antibodies against haematological cancer cell lines in vitroHarrison D Collier-Bain, Frankie F Brown, Adam J Causer, et al.
European Journal of Haematology|January 26, 2021
Efficacy and tolerability of VCD chemotherapy in a UK real-world dataset of elderly transplant-ineligible newly diagnosed myeloma patientsAlexandros Rampotas, Faouzi Djebbari, Fotios Panitsas, et al.
Plos One|January 11, 2022
Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patientsFaouzi Djebbari, Alexandros Rampotas, Fotios Panitsas, et al.
Pageof 7

Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
Leukemia|September 7, 2024
Plasma cell disorders supress mucosal anti-bacterial immunity: another dimension of immunoparesis in plasma cell neoplasmsSian Faustini, Y L Tracey Chan, Lilli Evans, et al.
British Journal of Haematology|September 4, 2025
Assessment and treatment of frail patientns living with multiple myeloma. A guideline on behalf of the UK Myeloma Research Alliance Frailty GroupSally Moore, Hannah Miller, Christopher Parrish, et al.
British Journal of Haematology|July 10, 2018
A new prognostic model for myeloma patients relapsing from upfront autologous transplantation based on ISS and PFS1Selina J Chavda, Paul M Maciocia, Pavlina Mesiri, et al.
British Journal of Haematology|May 18, 2026
Belantamab mafodotin-associated keratopathy: Clinical outcomes and management from two UK tertiary centresSarah Schimansky, Rebecca Cairns, Nicholas Cotton, et al.
British Journal of Haematology|February 12, 2026
High-throughput monoclonal gammopathy community monitoring programmeGaurav Agarwal, Lauren Campbell, Oluremi Carty, et al.
Brain, Behavior, & Immunity - Health|October 16, 2024
Characterising how a single bout of exercise in people with myeloma affects clonal plasma cell and immune effector cell frequency in blood, and daratumumab efficacy <i>in vitro</i>Harrison D Collier-Bain, Annabelle Emery, Frankie F Brown, et al.
British Journal of Haematology|August 3, 2021
COVID symptoms, testing, shielding impact on patient-reported outcomes and early vaccine responses in individuals with multiple myelomaKarthik Ramasamy, Ross Sadler, Sally Jeans, et al.
Scientific Reports|November 15, 2024
Downhill running does not alter blood C1q availability or complement-dependent cytotoxicity of therapeutic monoclonal antibodies against haematological cancer cell lines in vitroHarrison D Collier-Bain, Frankie F Brown, Adam J Causer, et al.
European Journal of Haematology|January 26, 2021
Efficacy and tolerability of VCD chemotherapy in a UK real-world dataset of elderly transplant-ineligible newly diagnosed myeloma patientsAlexandros Rampotas, Faouzi Djebbari, Fotios Panitsas, et al.
Plos One|January 11, 2022
Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patientsFaouzi Djebbari, Alexandros Rampotas, Fotios Panitsas, et al.
Pageof 7